Investment analysts at Maxim Group initiated coverage on shares of Nasus Pharma (NYSEAMERICAN:NSRX – Get Free Report) in a report released on Friday, Benzinga reports. The firm set a “buy” rating and a $7.00 price target on the stock. Maxim Group‘s target price would indicate a potential upside of 115.78% from the stock’s current price.
Nasus Pharma Trading Up 1.7%
NYSEAMERICAN NSRX opened at $3.24 on Friday. Nasus Pharma has a 12 month low of $1.98 and a 12 month high of $9.50. The company’s 50 day simple moving average is $3.59 and its 200 day simple moving average is $3.66.
Nasus Pharma (NYSEAMERICAN:NSRX – Get Free Report) last announced its quarterly earnings data on Monday, August 17th. The company reported ($0.27) earnings per share for the quarter. As a group, analysts predict that Nasus Pharma will post -0.84 EPS for the current fiscal year.
Nasus Pharma Company Profile
Nasus Pharma Ltd. is a specialty pharmaceutical company focused on developing intranasal powder-based medicines. Its proprietary platform is designed to deliver drug therapies through the nose, with the potential to support rapid administration without the need for injections or other conventional delivery methods.
The company’s development efforts are directed toward acute and emergency-care applications, including treatments for conditions in which rapid drug delivery may be important.
See Also
- Five stocks we like better than Nasus Pharma
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
- SaaS-Pocalypse II: Is ServiceNow’s Sell-Off Another Buying Opportunity?
- Robinhood Stock Is Down Nearly 37%—So Why Is Wall Street Still So Bullish?
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
